Hauv nruab nrab paj hlwb (CNS) kev txhim kho tshuaj, tus neeg sib tw uas ncav cuag lub hlwb tau tshem tawm thawj qhov teeb meem. Txawm hais tias nws koom nrog nws lub hom phiaj pharmacological muaj cov lus nug cais, thiab kev cuam tshuam plasma tsis tuaj yeem teb nws.
PlasmaPharmacokinetics (PK), cerebrospinal fluid (CSF) sampling, thiab cov ntaub so ntswg biodistribution piav qhia tias muaj tshuaj npaum li cas thiab nws mus qhov twg. Tsis muaj leej twg qhia ntau npaum li cas ntawm cov receptor tshwj xeeb yog nyob. Rau CNS kev kho mob qhov sib txawv tseem ceeb, vim hais tias cov tshuaj pharmacological feem ntau yog nyob ntawm kev mus txog qib txaus ntawm lub hom phiaj kev koom tes es tsis yog kev ua tiav lub hlwb ntsuas tau.
Positron emission tomography (PET) receptor imaging ntsuas uas nyob. Radiolabeled ligands khi reversibly rau cov receptors tshwj xeeb, thiab qhov kev hloov hauv ligand khi tom qab kev cuam tshuam ntawm pharmacological ntsuas seb cov tshuaj tau noj ntau npaum li cas.

Prisys nthuav tawm ib qho piv txwv ua haujlwm thaum lub sij hawm Prisys Biotech webinar ntawmmolecular duabhauv kev tshawb fawb tsis yog tib neeg primate (NHP). Txoj kev tshawb no siv [18F]Fallypride los ua raws li dopamine D2 / D3 receptor binding nyob rau hauv cynomolgus liab los ntawm 150-feeb dynamic PET acquisition, nrog rau intravenous haloperidol kev sib tw ntawm 120 feeb.
Cov ntaub ntawv no qhia tau hais tias PET dynamic li cas lub regional receptor binding, qhia pharmacological hloov chaw, thiab txhawb lub hom phiaj kev ntsuam xyuas nyob rau hauv preclinical CNS cov kev pab cuam.
1. Vim li cas tus neeg txais neeg nyob qhov tseem ceeb tshaj li qhov kev pom zoo PK
Receptor nyob yog qhov feem pua ntawm cov hom phiaj receptors khi los ntawm cov tshuaj ntawm ib lub sijhawm. Plasma concentration thiab tag nrho cov ntaub so ntswg raug piav qhia tias muaj tshuaj npaum li cas. Cov neeg nyob piav qhia tias cov tshuaj ua dab tsi ntawm tus receptor.
Rau dopamine D2 antagonists thiab ib nrab agonists, kev sib raug zoo ntawm plasma concentration thiab occupancy yog nonlinear thiab saturable. Nyob rau hauv tsawg concentrations, ib tug me ntsis nce nyob rau hauv raug tsim ib tug loj nce nyob rau hauv cov neeg nyob. Raws li kev khi mus txog saturation, kev nce ntxiv hauv cov concentration tsim cov txiaj ntsig me me.
Cov duab ntawd muaj qhov cuam tshuam ncaj qha rau kev xaiv koob tshuaj. Clinical PET cov kev tshawb fawb ntawm cov tshuaj antipsychotic tau tsim muaj kev koom tes ntawm D2 receptor occupancy, kho cov lus teb, thiab cov tsos mob extrapyramidal. Kev ntsuas cov neeg nyob yog li ntawd qhia tau hais tias tus neeg sib tw mus txog qib tsim nyog ntawm kev koom tes yam tsis muaj kev cuam tshuam ntau dua li cov kws tshuaj xav tau.
Tib lub logic siv rau lwm yam kev coj ua dopamine. D2 ib nrab agonist xav tau kev nyob txaus los tsim nws cov nyhuv thaum tawm hauv chav rau endogenous dopaminergic signaling. Cov tshuaj tsom rau cov receptors extrastriatal xav tau kev sib khi zoo nyob rau hauv cov cheeb tsam, thiab siab striatal uptake ib leeg tsis qhia nws.
2. [18F]Fallypride PET Measure yog dab tsi?
[18F]Fallypride yog hloov pauv benzamide radioligand nrog kev sib raug zoo rau dopamine D2-zoo li receptors, suav nrog D2 thiab D3 subtypes. Kev khi yog thim rov qab, yog li tib txoj kev taug qab tuaj yeem ua raws los ntawm kev koom tes thiab kev sib cais hauv ib qho kev sib tham.
Nws txoj kev sib raug zoo yog siab txaus los qhia txog kev khi rau hauv thaj chaw ntawm cov neeg txais neeg tsawg tsawg, suav nrog thaj chaw cortical thiab thalamic. Feem ntau lwm cov dopamine receptor tracers tau tsim rau cov cheeb tsam high-density thiab rov qab me ntsis usable teeb liab sab nraum lub striatum.
Fluorine-18 muaj lub cev ib nrab-lub neej ntawm li 110 feeb, ntev txaus rau ib tug dynamic raws tu qauv uas captures tus me nyuam, lub regional tsub zuj zuj, thiab ntxuav tawm nyob rau hauv ib tug tau txais.
Muaj ob qhov txwv kev txhais lus. [18F]Fallypride tsis cais D2 los ntawm D3, yog li lub teeb liab yog D2 / D3 khi thiab tsis muaj dab tsi tshwj xeeb. PET teeb liab siv kuj tsis sib npaug receptor tooj. Kev ntsuas hluav taws xob sib txuas ua ke cov khoom xa tuaj, tsis muaj kev faib tawm, kev sib khi tshwj xeeb, thiab kev sib tw kinetics, thiab kev sib cais cov khoom yuav tsum muaj kev tshuaj xyuas kinetic.
3. NHP Case: Dynamic PET Imaging nrog Haloperidol Challenge
Dopamine D2/D3 Receptor PET: [18F]Fallypride thiab Haloperidol Kev Sib Tw
Nyeem cov receptor muaj nyob hauv tib tsiaj, ua ntej thiab tom qab kev sib tw tshuaj.
Hauv qhov kev tshawb fawb no, Prisys nthuav tawm dynamic [18F]Fallypride PET hauv cynomolgus liab, siv 150-feeb kev tau los nrog kev sib tw haloperidol intravenous ntawm 120 feeb.
Vim li cas [18F]Fallypride, thiab qhov kev kawm tau tsim li cas:
- Binds dopamine D2-zoo li receptors, yog li lub regional teeb liab taug qab receptor muaj nyob rau hauv lub striatum thiab nyob rau hauv qis-density extrastriatal cheeb tsam xws li cortex thiab thalamus
- Fluorine-18 labeling (kwv yees li 110-feeb ib nrab-lub neej) txhawb nqa 150-feeb dynamic nrhiav tau hauv ib zaug
- Haloperidol muab rau ntawm 120 feeb raws li kev sib tw D2 antagonist, yog li kev hloov pauv tshwm sim hauv tib lub scan.
- Striatal thiab extrastriatal cheeb tsam piv rau lub sij hawm mus rau ncov thiab rau tracer tuav
Khaws cov tsiaj nyob rau hauv tib lub scanner yuav siv sij hawm inter-subject variability tawm ntawm qhov kev sib piv, thiab cov kev sib tw cais tshwj xeeb receptor khi los ntawm tus so ntawm lub teeb liab. Lub scan tsis yog receptor suav; nws ntsuas ligand binding, thiab binding muaj peev xwm los ntawm tus qauv kinetic.
Hais lus: Dr. Wei Liu, Prisys Biotechnologies.Cov ntaub ntawv los ntawm Prisys Biotechnologies molecular imaging platform.
Thov hu rau:bd@prisysbiotech.com.
Dr. Liu tus piv txwv siv [18F]Fallypride PET hauv cynomolgus liab los ua tus cwj pwm tracer tis thiab regional receptor binding nyob rau hauv lub hlwb ib txwm. Lub hom phiaj yog cov lus piav qhia hauv paus tsis yog tus qauv kab mob lossis tus neeg sib tw kho mob.
Qhov kev yuav khoom tau khiav rau 150 feeb. Thaum 120 feeb, haloperidol tau muab tso rau hauv txoj hlab ntshav raws li qhov kev sib tw pharmacological.
Striatal thiab extrastriatal cheeb tsam coj txawv txawv. Cov cheeb tsam Extrastriatal feem ntau peaked ua ntej thiab tshem tawm sai dua. Lub ob sab striata tau mus txog qhov siab tshaj tom qab thiab khaws cia ntev dua.
Receptor ceev piav qhia tus qauv. Nyob rau hauv ib cheeb tsam high-density xws li striatum, feem ntau ntawm cov teeb liab los ntawm kev khi tshwj xeeb. Qhov twg qhov ntom qis dua, cov khoom xa tuaj thiab cov khoom tsis tshwj xeeb muaj feem ntau ntawm nws.
Qhov txawv ntawd txwv txoj kev kawm tsim. Ib daim duab zoo li qub ntawm ib lub sijhawm teem tseg tsis tuaj yeem ua tus cwj pwm striatal thiab extrastriatal khi ib zaug, yog li lub sijhawm tau txais thiab cov phiaj xwm tsom xam yuav tsum suav rau hauv cheeb tsam kinetics.
Qhov kev sib tw haloperidol ntxiv ib qho kev sim tshuaj. Haloperidol yog dopamine receptor antagonist thiab sib tw nrog [18F]Fallypride rau tib qhov chaw sib khi. Tom qab noj tshuaj, kev sib txuas ntawm cov kab mob poob rau hauv thaj chaw uas lub teeb liab yog qhov tshwj xeeb D2 / D3 khi. Qhov kev hloov pauv ntawd txhawb nqa qhov tshwj xeeb thiab qhov thim rov qab ntawm lub teeb liab hauv cheeb tsam.
4. Yuav ua li cas yog tus neeg txais kev nyob thiab kev khi muaj peev xwm ua kom muaj nuj nqis?
Cov duab ib leeg tsis tuaj yeem nqa ib qho kev thov tshuaj tshuaj ntau. Feem ntau ntawm cov ntaub ntawv zaum nyob rau hauv lub sij hawm-activity nkhaus (TAC), uas traces radioactivity concentration nyob rau hauv ib cheeb tsam xaiv thoob plaws qhov tau txais. Nws cov duab qhia txog kev xa khoom, kev sib koom receptor, kev sib cais, thiab kev tshem tawm.
Rau reversible tracers, quantification feem ntau yog nyob ntawm ib cheeb tsam siv nrog negligible tshwj xeeb khi rau lub hom phiaj. Lub cheeb tsam ntawd kwv yees qhov kev faib tawm uas tsis muaj chaw nyob thiab tso cai rau kev tsom xam cais tshwj xeeb khi los ntawm tus so ntawm lub teeb liab.
Qhov ntsuas feem ntau tshaj tawm yog qhov tsis muaj peev xwm sib txuas tau (BPND), qhov piv ntawm tshwj xeeb tracer rau nondisplaceable tracer ntawm equilibrium nyob rau hauv lub assumption ntawm cov xaiv kinetic qauv. Cov qauv siv-cov ntaub so ntswg los yog lwm yam validated kinetic le caag kwv yees nws, nyob ntawm seb tracer thiab acquisition design.
Cov neeg nyob tom qab ntawd ua raws los ntawm kev sib piv ntawm kev sib khi muaj peev xwm ua ntej thiab tom qab kev sib tw tshuaj:
Receptor Nyob (%)=[(BPND, pib- PABND, tshuaj) / PABND, pib] × 100
Kev poob hauv BPNDTom qab noj tshuaj txhais tau tias tsawg dua qhov chaw tseem muaj nyob rau hauv radioligand. Raws li kev tshawb fawb kev xav, lub caij nplooj zeeg kwv yees li receptor occupancy.
Tus lej lej yog qhov yooj yim. Kev ntseeg tsis yog. Kev ruaj ntseg ntawm lub cev, kev nrhiav tau zoo ib yam, cov ntsiab lus hauv cheeb tsam raug, kho cov lus tsa suab, thiab cov qauv kinetic tsim nyog txhua tus pub rau hauv qhov kwv yees.
Qhov kev sib tw tsim hauv webinar siv tib lub hauv paus ntsiab lus hauv ib qho kev sib tham. Tsis txhob sib piv cov hauv paus ntsiab lus thiab kev kho tom qab kuaj xyuas, tus neeg saib xyuas thaiv tau muab thaum lub sijhawm tau txais ib qho dynamic, thiab kev hloov pauv yog nyeem ncaj qha los ntawm lub sijhawm ua haujlwm nkhaus. Tsawg dua qhov kev yees duab txhais tau tias tsawg dua ntawm kev sib tham sib txawv los tswj. Nws kuj tseem muab qhov hnyav rau ntawm qhov kev xaiv tsim: kev sib tw lub sijhawm, thaiv cov koob tshuaj, thiab qhov ntev ntawm kev tau txais cov khoom seem tom qab txhaj tshuaj tag nrho txiav txim siab seb qhov kev hloov pauv puas raug ntes zoo txaus los ntsuas.
5. Qhov Kev Sib Tw Ib Leeg Ib Leeg tuaj yeem ua tau dab tsi?
Ib qho kev sib tw ib koob tshuaj ntsuam xyuas qhov tshwj xeeb thiab thim rov qab lub hom phiaj khi. Nws tsis tsim kev sib raug zoo ntawm koob tshuaj.
Qhov kev txwv ntawd tseem ceeb thaum PET cov txiaj ntsig pub kev txiav txim siab txhim kho. Ib koob tshuaj tiv thaiv yog ib qho kev cuam tshuam. Kev txav chaw ntawm qhov chaw txhawb nqa lub hom phiaj-kho kev nyeem ntawv ntawm lub teeb liab, thiab tsis hais dab tsi txog qhov kev nyob mus li cas hla cov concentrations.
Kev sib raug zoo ntawm kev noj tshuaj ntau npaum li cas xav tau ntau qib koob tshuaj, qhov zoo tshaj plaws nrog plasma PK ntsuas ib sab yog li kev nyob tuaj yeem cuam tshuam nrog kev raug mob. Xws li daim duab qhia kev sib koom ua ke tiv thaiv kev sib koom tes, txheeb xyuas qhov cuam tshuam ntawm kev sib txuas rau ib pawg neeg nyob, thiab txhawb kev xaiv tshuaj noj tshuaj.
Peb cov ntsiab lus ntxiv dais ntawm kev txhais lus.

Pharmacological selectivity:haloperidol tsis xaiv rau D2 / D3. Nws kuj cuam tshuam nrog sigma-1 thiab serotonin 5-HT2A receptors. Nws siv los ua tus neeg saib xyuas thaiv yog li ntawd nyeem tawm tsam qhov kev faib tawm hauv cheeb tsam thiab qhov pom kev hloov pauv, tsis yog pov thawj tias txhua qhov cuam tshuam los ntawm D2 / D3.
Physiological tej yam kev mob:Kev siv tshuaj loog thiab kev hloov pauv lub cev muaj feem cuam tshuam rau cov ntshav hauv hlwb, kev xa cov kab mob, thiab tejzaum nws endogenous dopaminergic kev ua haujlwm. Cov kev hloov pauv no xav tau kev tswj hwm thiab cov ntaub ntawv thoob plaws hauv kev sib ntsib duab.
Cov neeg nyob nrog rau kev ua tau zoo:Kev ua neej nyob qhia txog kev sib koom ua ke, tsis yog kev pab kho mob. Ib lub tebchaw tuaj yeem tuav nws cov receptor ntau yam tsis tau tsim cov lus teb rau nqes hav.
Receptor imaging yog li ntawd koom nrog rau lwm cov tshuaj pharmacodynamic endpoints es tsis sawv rau lawv.
6. Vim li cas thiaj siv Non-Human Primates rau Dopamine Receptor PET Studies?
NHP imaging suits ntau CNS receptor ua hauj lwm, tshwj xeeb tshaj yog thaum lo lus nug npog cov neeg nyob hauv striatal thiab extrastriatal ua ke.
Rodent PET yog tsim tau zoo, tab sis lub hlwb me me txwv lub cheeb tsam kom muaj nuj nqis. Ib feem ntim cov teebmeem loj zuj zus ib zaug ib cheeb tsam ntawm kev txaus siab mus txog qhov kev daws teeb meem spatial ntawm lub scanner, thiab kev sib cais cov qauv uas nyob ib sab yuav tsis ntseeg. Me me extrastriatal cheeb tsam raug kev txom nyem feem ntau.
Lub paj hlwb loj dua tso cai rau kev nthuav dav ntawm striatum, thalamus, thiab thaj chaw cortical. NHPs kuj tseem txuas rau nas kws tshuaj thiab kev kho mob neuroimaging: lub koom haum neuroanatomical thiab dopaminergic system zoo ib yam li tib neeg kev npaj kom txaus los ua kev faib khoom, kev sib khi, thiab cov tshuaj teb tshuaj ntsuas tau hauv qhov chaw txhais lus.
Rov ua dua cov duab hauv tib tus tsiaj yog qhov zoo dua. Nyob rau hauv-kev tsim qauv txo cov kev cuam tshuam ntawm inter-tus neeg sib txawv nyob rau hauv receptor muaj thiab physiology, uas tseem ceeb thaum cov kev xav tau me me los yog thaum khi yuav tsum tau taug qab lub sij hawm.
Cov ntaub ntawv NHP tsis hloov pauv nrog tib neeg PET ntsuas. Physiology, tracer kinetics, tshuaj loog, thiab kev sim tshuaj sib txawv, thiab cov kev sib txawv no yuav tsum tau ua thaum kev tshawb pom ntau tau txhais. Matched imaging modalities thiab analytical txoj kev nqaim lub methodological sib txawv.
7. Integrating Receptor Imaging into CNS Drug Development
Receptor PET pab txhawb feem ntau thaum nws zaum hauv cov tshuaj siv dav dav thiab PK / PD lub tswv yim.
Lub hom phiaj kev soj ntsuam kev koom tes yog ua ntej. Ua ntej cog lus rau kev tshawb fawb txog kev ua tau zoo, ib pab neeg tuaj yeem tsim tau seb tus neeg sib tw nkag mus rau hauv lub hlwb thiab tuav nws cov receptor ntawm cov teeb meem cuam tshuam.
Kev xaiv koob tshuaj raws li nram no. Kev ntsuas nyob thoob plaws ntau qib koob tshuaj thiab kev koom ua ke nrog plasma PK muab kev sib raug zoo ntawm kev nyob ua ke uas muab lub hauv paus rau kev xaiv cov koob tshuaj hauv cov kev tshawb fawb tom qab, ua haujlwm kho mob thaum ntxov.
Cov neeg sib tw sib piv yog qhov thib peb siv. Qhov twg ntau lub tebchaw sib koom lub hom phiaj molecular, PET cov ntaub ntawv muaj nyob hauv vitro binding affinity thiab cov pa PK, thiab tso cai rau hauv vivo kev koom tes los sib piv ntawm qhov sib tw.
Nyeem nrog rau lwm qhov kawg, cov kev ntsuas no piav qhia txog qhov kev pab cuam ntau dua.
|
Kev ntsuas
|
Cov lus nug tseem ceeb tau hais
|
|
Plasma PK
|
Ntau npaum li cas cov tshuaj muaj nyob rau hauv lub systemic ncig?
|
|
CSF concentration
|
Qhov ntsuas tshuaj concentration hauv CSF yog dab tsi?
|
|
Biodistribution duab
|
Cov khoom sib txuas lossis cov khoom siv radiolabeled faib qhov twg?
|
|
Receptor PET
|
Ntau npaum li cas ntawm lub hom phiaj muaj rau kev sib txuas ntawm radioligand, thiab qhov no hloov pauv li cas tom qab kev tswj hwm tshuaj?
|
|
Kev ua haujlwm thiab kev coj tus cwj pwm kawg
|
Puas yog lub hom phiaj kev koom tes txhais ua cov tshuaj tshuaj ntsuas tau?
|
Kev sib xyaw ua ke ntawm cov kev ntsuas no txuas rau qhov raug, lub hom phiaj kev koom ua ke, thiab cov lus teb ntawm cov tshuaj pharmacological hauv qab.
8. Kev txiav txim siab thiab kev txwv ntawm NHP Receptor PET
Quantitative receptor PET muab nqi zog ua tib zoo tsim thiab tracer-specific validation.
Qhov kev siv-thaj tsam qhov kev xav tau txhawb nqa ntau txoj hauv kev kom muaj nuj nqis. Cov cheeb tsam uas tau xaiv yuav tsum muaj qhov tsis txaus ntseeg tshwj xeeb khi rau lub hom phiaj, thiab nws qhov kev tsim nyog yuav tsum tau tsim rau cov tracer thiab hom siv.
Motion tseem ceeb thaum lub sij hawm ntev dynamic acquisitions. Cov kev txav me me hloov pauv kev sau npe anatomical thiab cuam tshuam lub sijhawm ua haujlwm hauv cheeb tsam nkhaus, uas nthuav tawm mus rau hauv qhov kev kwv yees.
Test-retest variability xav tau tus yam ntxwv thaum twg ib qho kev hloov hauv kev khi yog qhov tseem ceeb kawg. Yog tsis muaj lub hauv paus kev sib txawv ntawm daim duab, cov nyhuv pharmacological tiag tiag thiab kev ntsuas qhov sib txawv zoo ib yam.
Tracer khi cov yam ntxwv thiab kev sib cuam tshuam ntawm lub hom phiaj yuav tsum tau kuaj ua ntej. Qhov twg yuav tsum muaj cov ntaub ntawv tshwj xeeb subtype, [18F]Fallypride tsis tuaj yeem cais D2 los ntawm D3 kev koom tes.
Cov kev cai no tau teeb tsa cov xwm txheej rau kev siv receptor PET: ib qho tracer uas tsim nyog, txhais cov ntsiab lus ntawm qhov kawg, thiab cov txheej txheem tsom xam pom zoo ua ntej txoj kev tshawb fawb pib.
Xaus
[18F]Fallypride PET nyob rau hauv cynomolgus liab qhia dab tsi receptor imaging ntxiv nyob rau hauv vivo: regional D2/D3 khi, striatal thiab extrastriatal kinetics ua raws li nyob rau hauv ib tug 150-feeb dynamic acquisition, thiab pharmacological hloov chaw tom qab ib tug intravenous haloperidol sib tw ntawm 120 feeb.
Qhov kev pab cuam dav dua yog cov lus nug uas nws teb. Receptor PET teeb tsa seb tus neeg sib tw koom nrog nws lub hom phiaj ntawm qhov raug, uas tsis muaj ntshav PK nkhaus, CSF qauv, lossis cov duab biodistribution daws nws tus kheej.
Nyeem nrog cov qauv PK, CSF qauv, biodistribution imaging, thiab functional pharmacodynamic endpoints, cov ntaub ntawv nyob ua kom tiav cov saw los ntawm raug rau cov tshuaj pharmacological.
Kev nthuav tawm, lub hom phiaj kev koom tes, thiab kev kho mob zoo nyob sib txawv. Ua kom lawv sib txawv yog qhov ua rau kev tshawb nrhiav kev txhais lus qhia thiab kev txiav txim siab txhim kho tiv thaiv.
Molecular Imaging Webinar Case Series
Tsab ntawv xov xwm no kaw rau ntawm Prisys Biotech webinar series ntawm molecular imaging hauv NHP kev tshawb fawb. Txhua feem coj ib lo lus nug.
Thawj ua rawstag nrho lub cev biodistribution imaginghauv NHPs nrog iodine-125 SPECT, nug seb cov ntawv sau ua ke faib thoob plaws hauv nruab nrog cev li cas. Qhov thib ob nug seb puas muaj kev siv tshuaj intranasally mus txog lub hlwb, thiab sivkev xa ntawm qhov ntswg mus rau hlwbntsuas los ntawm SPECT los teb nws. Qhov thib peb ua haujlwm dhau losActinium-225 tib neeg koob tshuaj projectionlos ntawm NHP cov ntaub ntawv duab, suav nrog kev kwv yees cov koob tshuaj absorbed thiab kev kwv yees ntawm tib neeg. Plaub taug qablongitudinal tau PETnyob rau hauv ib tug rhesus macaque qauv. Qhov thib tsib thovVMAT2 PEBnyob rau hauv ib tug tsis yog tib neeg primate qauv ntawmTus kab mob Parkinsontxhawm rau txheeb xyuas qhov tsis txaus dopaminergic hauv vivo.
|
Tsis muaj.
|
Ntsiab lus
|
Cov lus nug tseem ceeb
|
|
1
|
Yuav ua li cas cov tshuaj radiolabeled faib thoob plaws hauv lub cev thaum lub sijhawm?
|
|
|
2
|
Puas yog ib qho tshuaj intranasally muab nkag mus rau lub hlwb, thiab nws khaws cia ntev npaum li cas?
|
|
|
3
|
Yuav ua li cas preclinical imaging ntaub ntawv txhawb absorbed-dose kwv yees thiab tib neeg kev ua ub no projection?
|
|
|
4
|
Yuav ua li cas tau-koom nrog cov duab teeb liab hloov lub sij hawm?
|
|
|
5
|
Puas yog dopaminergic tsis txaus cuam tshuam nrog Parkinsonian pathology tuaj yeem suav nrog hauv vivo?
|
|
|
6
|
Yuav ua li cas PET imaging ntsuam xyuas qhov muaj receptor thiab kev koom tes ntawm pharmacological lub hom phiaj?
|
Nyeem raws li cov txheej txheem, rau qhov txav los ntawm kev xa tawm los ntawm kev xa khoom, dosimetry, kab mob kev loj hlob, thiab dopaminergic tsis txaus rau receptor muaj, uas yog lub ntsiab lus ntawm kev nyeem cov duab pib teb cov lus nug kws tshuaj.
Xaiv ib txoj kev imaging raws li cov lus nug scientific. Cov kev sib txawv, cov txheej txheem kev yuav khoom, thiab kev tshuaj ntsuam xyuas rov qab cov ntaub ntawv ntxiv, thiab kev sib xyaw ua ke ntxiv dag zog rau kev txhais cov ntaub ntawv kho mob preclinical.
Rau cov ntsiab lus ntxiv, cov koob yog nrog los ntawm cov lus piav qhia txog kev siv cov duab molecular hauv NHP kev tshawb fawb thiab kev txhim kho tshuaj txhais lus.
Cov lus nug uas nquag nug
Q: Dab tsi yog dopamine D2 / D3 receptor nyob hauv PET duab?
A: Dopamine D2 / D3 receptor occupancy yog qhov feem pua ntawm cov receptors uas muaj ua ke los ntawm cov tshuaj. PET imaging nrog ib tug reversible radioligand xws li [18F]Fallypride quantifies qhov kev hloov nyob rau hauv ligand khi tom qab ib tug kws tshuaj, uas muab ib tug nyob rau hauv vivo ntsuas ntawm lub hom phiaj kev koom tes.
Q: Vim li cas [18F]Fallypride siv rau dopamine receptor imaging?
A: [18F]Fallypride muaj kev sib raug zoo siab rau D2-zoo li receptors thiab cov ntawv ceeb toom khi rau hauv ob qho tib si striatal thiab extrastriatal lub paj hlwb. Reversible binding ua rau nws haum rau dynamic PET cov kev tshawb fawb thiab pharmacological hloov chaw thwmsim.
Q: Lub hom phiaj ntawm kev sib tw haloperidol thaum [18F]Fallypride PET yog dab tsi?
A: Haloperidol yog qhov sib tw dopamine receptor antagonist. Muab thaum lub sijhawm tau txais PET dynamic, nws cia cov kws tshawb fawb soj ntsuam qhov kev hloov pauv hauv [18F]Fallypride khi. Ib qho kev txo qis hauv cheeb tsam kev sib txuas lus txhawb nqa kev nyeem ntawv uas cov teeb liab suav nrog tshwj xeeb, thim rov qab D2 / D3 receptor binding.
Q: Kev sib tw PET ib zaug puas tuaj yeem tsim kom muaj kev sib raug zoo ntawm koob tshuaj?
A: Tsis yog. Ib qho kev sib tw ib zaug qhia txog kev hloov pauv tshuaj ntawm ib qho kev cuam tshuam. Kev sib raug zoo ntawm koob tshuaj yuav tsum muaj ntau qib, qhov zoo tshaj plaws nrog kev ntsuas ntshav PK uas cuam tshuam txog kev cuam tshuam rau cov neeg txais neeg nyob.
Q: Dab tsi yog qhov txawv ntawm receptor occupancy thiab kev siv yeeb tshuaj?
A: Receptor occupancy ntsuas lub hom phiaj kev koom tes. Kev ua tau zoo ntawm cov tshuaj yog hais txog lub peev xwm ntawm cov khoom sib txuas los tsim nws cov tshuaj pharmacological lossis kev kho mob. Cov neeg nyob siab tsis tas yuav txhais ua cov lus teb muaj txiaj ntsig zoo, yog li ob qho kev ntsuas muaj nyob rau hauv kev ntsuam xyuas ntawm tus neeg sib tw CNS.
Q: Vim li cas cov primates tsis yog tib neeg muaj txiaj ntsig rau CNS receptor PET kev tshawb fawb?
A: NHPs muab lub hlwb loj dua rau thaj tsam PET tsom xam thiab kaw cov neuroanatomical thiab lub cev zoo sib xws rau tib neeg. Rov ua dua cov duab nyob rau hauv tib tus tsiaj kuj tso cai rau longitudinal kev soj ntsuam ntawm receptor binding thiab pharmacological teb.













